Christopher Leo, Ph.D., Senior Vice President, has over 10 years of experience in providing strategic advisory support to life sciences clients.  Chris joined Back Bay from Genzyme, where he led strategic & competitive planning projects for the company’s $2 billion Rare Genetic Disease and $500 million Biosurgery business units. Chris supported both the brand teams on commercial issues related to strategic marketing and competitive positioning, as well as the R&D organization on the assessment of new market opportunities.  Prior to Genzyme, Chris was a Director with Leerink Swann’s Strategic Advisory group, where he led assignments comprising commercial, R&D, and growth strategies for both big pharma/med-tech and emerging growth clients. Chris was also a Principal in Wood Mackenzie’s life science consulting practice, and prior to that, was Director of the Belfer Cancer Genomics Center at the Dana Farber Cancer Institute.  Dr. Leo completed his doctorate in Biochemistry and Molecular Pharmacology at the University of Massachusetts Medical School, a post-doctoral fellowship in the Department of Pathology at Harvard Medical School, and earned his undergraduate degree in Biology from the College of the Holy Cross.